[Therapeutic effectiveness of furazolidone and difuracil (PAP-49) in experimental staphylococcal and Escherichia septicemia].
The therapeutic efficacy of a new nitrofuran, N-(5-nitrofurilidene)-5-nitrofuran-2-(N'-acetyl)carboxamidra zone (difuracil or PAP-49) in experimental staphylococcal and Coli septicemia was stated and compared to that of furazolidone. It was shown in the models of staphylococcal and Coli septicemia of albino mice that by its therapeutic efficacy difuracil (PAP-49) was 1.3 times more active as furazolidone and by 1-2 days earlier eradicated the pathogens in the host.
Terekhov
V I
VI
Pavlov
P A
PA
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy*; D004195:Disease Models, Animal; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005664:Furazolidone / Q000627:therapeutic use*; D051379:Mice; D009581:Nitrofurans / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D009581:Nitrofurans; C095288:difuracil; D005664:Furazolidone
Effektivnost' terapevticheskogo deĭstviia furazolidona i difuratsila (PAP-49) pri eksperimental'noĭ stafilokokkovoĭ i ésherikhioznoĭ septitsemii.